Skip to content
ClinCalc Pro
Menu
Antifibrotic

Pirfenidone

Brand names: Esbriet

Pirfenidone is an oral antifibrotic agent used to treat idiopathic pulmonary fibrosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It has antifibrotic and anti-inflammatory actions, attenuating fibroblast proliferation and the production of fibrosis-associated mediators and collagen, although its precise mechanism is not fully defined.

Prescribing in practice

  • Photosensitivity and rash are common, so strict sun protection and avoidance of strong sunlight are essential.
  • Hepatotoxicity can occur, requiring liver function testing before and during treatment with dose adjustment for derangement.
  • Gastrointestinal upset is common; taking doses with food improves tolerability, and smoking can reduce drug exposure.

Monitoring

Check liver function before starting and periodically during treatment, and monitor for skin reactions, gastrointestinal effects and weight loss.

Counselling the patient

  • Use high-factor sun cream, cover up and avoid sunbeds while taking this medicine.
  • Take the capsules with food to reduce nausea and report yellowing of the skin or eyes.
  • Tell your doctor if you smoke, as it can affect how this medicine works.

Evidence & guidelines

The ASCEND and CAPACITY trials showed that pirfenidone slows lung function decline in idiopathic pulmonary fibrosis, supporting NICE-recommended use.

Reference: ASCEND Trial (King et al, NEJM 2014); NICE TA379; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.